Castle Biosciences, Inc. (CSTL) Q4 FY25 Earnings Call

TissueCypher momentum supports growth, but 2026 guidance embeds limited Advanced AD TX contribution and continued profitability pressure [20][31].

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-03-01
Length46 minutes
EPS$-0.08
Revenue$83.0M
Revenue consensus$81.2M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All CSTL earnings ยท Back to CSTL overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.